All In Biotech

Drug Trial Radar · NCT07155174

A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer

A Phase 2 Randomized, Open Label, Multicenter Study to Evaluate the Optimal Dose, Safety, and Efficacy of ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Subjects With Previously Untreated Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 180 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

180

Planned (sponsor's estimate)

Start

Nov 25, 2025

Primary completion

Apr 2029

Study completion Sep 2031

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Sep 4, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Small cell lung cancer (SCLC) is characterized by aggressive and rapid growth and a tendency to develop early spread to distant sites including mediastinal lymph nodes, liver, bones, adrenal glands, and brain. The purpose of this study is to assess safety, dose, change in disease activity of ABBV-706 given with atezolizumab, compared to standard of care (SOC) treatment (etoposide, carboplatin, atezolizumab, and optional lurbinectedin). ABBV-706 is an investigational drug being developed for the treatment of SCLC. There are multiple treatment arms in this study. Participants will either receive ABBV-706 given with atezolizumab, at 1 of 2 doses, or SOC. Approximately 180 adult participants will be enrolled in the study across sites worldwide. In the safety lead-in, participants with SCLC will receive intravenous (IV) ABBV-706 in 1 of 2 doses with IV atezolizumab, or IV SOC. In the expansion portion of the study, participants with SCLC will receive IV ABBV-706 in 1 of 2 doses with atezolizumab, or IV SOC, until the optimal dose of ABBV-706 is determined. The estimated duration of the study is up to 69.5 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, questionnaires, and scans.

Conditions

  • Small Cell Lung Cancer

Interventions

  • ABBV-706Drug

    Intravenous (IV) Infusion

  • AtezolizumabDrug

    IV Infusion

  • EtoposideDrug

    IV Infusion

  • CarboplatinDrug

    IV Injection

  • CarboplatinDrug

    IV Infusion

  • LurbinectedinDrug

    IV Infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Adverse Events (AE)sTime frame: Up to 69.5 Months
  2. Progression-Free Survival (PFS) Based on Investigator AssessmentTime frame: Up to Approximately 24 Months

Locations

70 sites in 13 countries. Site status is shown where the registry gives one.

  • Yale University School of Medicine /ID# 278181

    New Haven, Connecticut · Recruiting

  • University of Florida College of Medicine /ID# 277496

    Gainesville, Florida · Recruiting

  • Ocala Oncology Center /ID# 278269

    Ocala, Florida · Recruiting

  • Moffitt Cancer Center /ID# 277573

    Tampa, Florida · Recruiting

  • Fort Wayne Medical Oncology And Hematology /ID# 277336

    Fort Wayne, Indiana · Recruiting

  • Baptist Health Lexington /ID# 277729

    Lexington, Kentucky · Recruiting

  • Dana-Farber Cancer Institute /ID# 277732

    Boston, Massachusetts · Recruiting

  • Henry Ford Hospital - Detroit /ID# 277218

    Detroit, Michigan · Recruiting

  • Missouri Cancer Associates /ID# 278299

    Columbia, Missouri · Recruiting

  • University Hospitals Cleveland Medical Center /ID# 277556

    Cleveland, Ohio · Recruiting

  • The University of Texas MD Anderson Cancer Center /ID# 277929

    Houston, Texas · Recruiting

  • Virginia Cancer Specialists - Fairfax /ID# 278298

    Fairfax, Virginia · Recruiting

  • Groupe Sante CHC - Clinique du MontLegia /ID# 276783

    Liège, Belgium · Recruiting

  • Grand Hopital de Charleroi - Les Viviers /ID# 276897

    Charleroi, Hainaut, Belgium · Recruiting

  • Jessa Ziekenhuis - Campus Virga Jesse /ID# 276781

    Hasselt, Limburg, Belgium · Recruiting

  • AZ Maria Middelares /ID# 277027

    Ghent, Oost-Vlaanderen, Belgium · Recruiting

  • Cancer Hospital - Chinese Academy of Medical Sciences /ID# 277167

    Beijing, Beijing Municipality, China · Recruiting

  • Henan Cancer Hospital /ID# 277059

    Zhengzhou, Henan, China · Recruiting

  • Union Hospital Tongji Medical College /ID# 277912

    Wuhan, Hubei, China · Recruiting

  • The First affiliated hospital of Nanchang University /ID# 277247

    Nanchang, Jiangxi, China · Recruiting

  • Shanghai East Hospital /ID# 277111

    Shanghai, Shanghai Municipality, China · Recruiting

  • Shanghai Pulmonary Hospital /ID# 276960

    Shanghai, Shanghai Municipality, China · Recruiting

  • West China Hospital of Sichuan University /ID# 277852

    Chengdu, Sichuan, China · Recruiting

  • Evangelische Lungenklinik Berlin /ID# 277094

    Berlin, Germany · Recruiting

  • Lungenfachklinik Immenhausen /ID# 278005

    Immenhausen, Hesse, Germany · Recruiting

  • Universitaetsklinikum Giessen und Marburg GmbH /ID# 277466

    Marburg, Hesse, Germany · Recruiting

  • Rambam Health Care Campus- Haifa /ID# 276663

    Haifa, Israel · Recruiting

  • Hadassah Medical Center-Hebrew University /ID# 276662

    Jerusalem, Israel · Recruiting

  • Meir Medical Center /ID# 277292

    Kefar Sava, Central District, Israel · Recruiting

  • Assuta Ashdod Medical Center /ID# 276661

    Ashdod, Southern District, Israel · Recruiting

  • The Chaim Sheba Medical Center /ID# 276660

    Ramat Gan, Tel Aviv, Israel · Recruiting

  • Fondazione Policlinico Universitario Campus Bio-Medico /ID# 277744

    Roma, Italy · Recruiting

  • IRCCS Ospedale San Raffaele /ID# 276793

    Milan, Milano, Italy · Recruiting

  • IRCCS Istituti Fisioterapici Ospitalieri-Istituto Nazionale Tumori Regina Elena /ID# 276792

    Rome, Roma, Italy · Recruiting

  • Azienda Ospedaliero Universitaria San Luigi Gonzaga /ID# 276789

    Orbassano, Torino, Italy · Recruiting

  • National Cancer Center Hospital East /ID# 277239

    Kashiwa-shi, Chiba, Japan · Recruiting

  • Shizuoka Cancer Center /ID# 277243

    Sunto-gun, Shizuoka, Japan · Recruiting

  • Tokyo Metropolitan Komagome Hospital /ID# 277335

    Bunkyo Ku, Tokyo, Japan · Recruiting

  • National Cancer Center Hospital /ID# 277237

    Chuo-Ku, Tokyo, Japan · Recruiting

  • Wakayama Medical University Hospital /ID# 277260

    Wakayama, Wakayama, Japan · Recruiting

Showing 40 of 70 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.